The next focusIR Investor Webinar takes place tomorrow with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEden Regulatory News (EDEN)

Share Price Information for Eden (EDEN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 4.30
Bid: 4.10
Ask: 4.50
Change: 0.00 (0.00%)
Spread: 0.40 (9.756%)
Open: 4.30
High: 4.30
Low: 4.30
Prev. Close: 4.30
EDEN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AGM Statement

26 Jun 2014 12:37

RNS Number : 6465K
Eden Research plc
26 June 2014
 



Eden Research Plc

("Eden" or "Company")

 

AGM Statement

 

Eden Research plc (AIM: EDEN), the AIM listed natural micro-encapsulation company, held its Annual General Meeting today at mid-day at The Four Pillars Hotel, Ducklington Lane, Witney OX28 4EX.

 

Following the formal proceedings of the meeting, at which all resolutions were duly passed, the Chairman, Tom Lupton, made the following statement:

 

"In the recently published 2013 Eden Report and Accounts, I gave shareholders a detailed update of the Company's development and trading position. I do not propose to repeat this at great length, however I would like to highlight certain key points which I feel, show that Eden is developing into a commercially successful business.

 

3AEY

"EU approval for the active substances in our first plant protection product, the terpene based fungicide 3AEY, was granted in May 2013 and we expect to complete the EU regulatory process this year. This means that we are less than a year away from 'off the shelf' products being approved. This will allow sales of 3AEY to begin through our licensing partners and, we hope, will provide sustained long term revenues.

 

Encapsulation

"Eden has branded its unique, natural encapsulation technology as GO-E Inside™, which will enable us to build brand recognition and form a basis for all future products developed by Eden and its partners. The first sales of products using GO-E Inside™ have been made by our licensee, TerpeneTech Limited. This is clearly a significant milestone and will result in royalties being paid to Eden.

 

Outlook

"The short-term picture is that of increasing revenues and deal flow. The Board plans to reorganise the business to maximise the value of our intellectual property portfolio. This will give Eden a clearer focus and allow us to strengthen the management team to address the challenges faced in the wide range of sectors where our encapsulation technology may be utilised.

 

"From what I have said to you here, as well as in the Chairman's Report, you will hopefully see that there is a lot happening at Eden. Our aim is to make Eden a leader in natural encapsulation technologies and for GO-E Inside™ to become a globally recognised brand. I believe that we now have a very firm foundation upon which to achieve this."

 

Eden Research plc

www.edenresearch.com

Clive Newitt, Managing Director

Tel: 01993 862 761

Alex Abrey, Chief Financial Officer

W H Ireland Limited

www.wh-ireland.co.uk

John Wakefield

Tel: 0117 945 3471

Walbrook PR Ltd

Tel: 020 7933 8780 or eden@walbrookpr.com

Paul McManus

Mob: 07980 541 893

Notes:

 

Eden is an early stage revenue company with intellectual property and expertise in encapsulation, terpenes and environmentally friendly technologies to provide naturally occurring solutions to the global agrochemicals industry, the animal health industry, and consumer products.

 

Eden's encapsulation technology harnesses the biocidal efficacy of naturally occurring chemicals produced by plants (terpenes) and can also be used with hydrophobic compounds both natural and synthetic. The technology uses yeast cells to deliver a slow release of natural compounds for agricultural and non-agricultural uses. Terpenes are already widely used in the food flavouring, cosmetic and pharmaceutical industries.

 

Historically, terpenes have had limited commercial use in the agrochemical sector due to their volatility, phytotoxicity and poor solubility. Eden's platform encapsulation technology provides a unique, environmentally friendly solution to these problems and enables terpenes to be used as effective, low-risk agrochemicals.

 

With leading consultants in their respective fields, the Company is developing these technologies through innovative research and a series of commercial production, marketing and distribution partnerships.

 

The Company has a number of patents and has a pipeline of products at differing stages of development targeting specific areas of the global agrochemicals industry. To date, the Company has invested in the region of £12m in developing and protecting its intellectual property. Revenues earned by the Company have been modest whilst the Company has concentrated on securing patent protection for its intellectual property, identifying suitable industrial partners and entering into licence agreements.

 

Eden was admitted to trading on AIM on 11 May 2012 and trades under the symbol EDEN.

 

For more information about Eden, please visit www.edenresearch.com

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AGMFFMBTMBJTBAI
Date   Source Headline
9th May 20247:00 amRNSInvestor Presentation via Investor Meet Company
7th May 20247:01 amRNSAppointment of Non-Executive Director
7th May 20247:00 amRNSPreliminary results for the year ended 31 Dec 2023
31st Jan 20247:00 amRNSBoard Change
22nd Jan 20247:00 amRNSTrading Update
19th Jan 20243:00 pmRNSHolding(s) in Company
9th Jan 20247:01 amRNSMevalone Approval in the State of California
18th Dec 20237:00 amRNSEcovelexâ„¢2023 Approval in Italy
28th Nov 20237:00 amRNSSmall Cap Virtual Investor Conference
1st Nov 20237:00 amRNSChange of Nominated Adviser and Broker
9th Oct 20234:44 pmRNSHolding(s) in Company
9th Oct 20234:39 pmRNSHolding(s) in Company
9th Oct 202312:46 pmRNSHolding(s) in Company
5th Oct 20237:00 amRNSCompletion of Conditional Placing
29th Sep 20237:01 amRNSHalf Yearly Report
29th Sep 20237:00 amRNSCapital Raising Update
31st Aug 20236:25 pmRNSGrant of Awards under Long-Term Incentive Plan
17th Aug 20239:27 amRNSResult of GM and Capital Raising update
16th Aug 20237:00 amRNSFirst Order For Ecovelex
2nd Aug 20233:22 pmRNSResult of Retail Offer
28th Jul 20235:00 pmRNSRetail Offer
28th Jul 20235:00 pmRNSPlacing and Retail Offer
3rd Jul 20237:00 amRNSRegulatory Application for Ecovelex in the UK
30th Jun 20239:17 amRNSResult of AGM
29th Jun 20237:00 amRNSAGM Statement
15th Jun 20237:00 amRNSAppointment of New Product Distributor – Colombia
9th Jun 20234:29 pmRNSHolding(s) in Company
7th Jun 20237:00 amRNSPublication of Annual Report and Notice of AGM
5th Jun 20234:47 pmRNSHolding(s) in Company
30th May 20237:00 amRNSEden and Corteva seek to bring Ecovelex to market
17th May 20237:00 amRNSExercise of Options
15th May 20237:00 amRNSMevalone authorisation in New Zealand
12th May 20237:00 amRNSRegulatory approvals in California and Florida
5th May 20237:00 amRNSPreliminary results for the year ended 31 Dec 2022
17th Apr 20237:00 amRNSRegulatory authorisation for Mevalone in Poland
23rd Mar 20237:00 amRNSUS State Regulatory Approvals Update
30th Jan 20237:00 amRNSFirst Mevalone authorisation for domestic use
10th Jan 20237:00 amRNSTrading Update
15th Dec 20222:01 pmEQSEden Research signs new Mevalone distribution deal
15th Dec 20227:00 amRNSDistribution Agreement for Mevalone in France
30th Nov 20227:00 amRNSOrganic Certification in Greece
24th Oct 202212:00 pmRNSAIM Rule 17 Notification
3rd Oct 20224:39 pmRNSHolding(s) in Company
30th Sep 20227:00 amRNSEden Half Yearly Report
28th Sep 20228:46 amRNSAppointment of Auditor
27th Sep 20225:08 pmEQSEden granted US EPA regulatory approval
26th Sep 20227:00 amRNSEden granted US EPA regulatory approval
2nd Sep 20227:00 amRNSAppointment of Non-Executive Director
22nd Aug 20227:00 amRNSTrading Update
7th Jul 20227:00 amRNSExercise of Options

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.